Scarica l'app Stockscreener
5.195
6.58%
0.325
Precedente Chiudi:
$4.87
Aprire:
$4.89
Volume 24 ore:
804.36K
Relative Volume:
1.77
Capitalizzazione di mercato:
$261.93M
Reddito:
$230.47M
Utile/perdita netta:
$30.28M
Rapporto P/E:
8.5164
EPS:
0.61
Flusso di cassa netto:
$38.86M
1 W Prestazione:
+59.70%
1M Prestazione:
+53.11%
6M Prestazione:
+78.36%
1 anno Prestazione:
+43.78%
Intervallo 1D:
$4.87
$5.33
Intervallo di 1 settimana:
$3.05
$5.33
Portata 52W:
$2.225
$5.33
Puma Biotechnology Inc Stock (PBYI) Company Profile
Nome
Puma Biotechnology Inc
Settore
Industria
Telefono
(424) 248-6500
Indirizzo
10880 WILSHIRE BLVD., LOS ANGELES, CA
Confronta PBYI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.20 | 244.30M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.63 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.00 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.49 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.68 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
303.19 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Underperform |
| 2019-10-08 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-10 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2019-01-17 | Iniziato | Leerink Partners | Mkt Perform |
| 2019-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-11-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-11-02 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Iniziato | Goldman | Sell |
| 2018-05-11 | Reiterato | Stifel | Buy |
| 2017-11-10 | Reiterato | Citigroup | Buy |
| 2017-11-10 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Reiterato | Stifel | Buy |
| 2017-09-11 | Reiterato | Credit Suisse | Outperform |
| 2017-07-10 | Ripresa | Leerink Partners | Outperform |
| 2017-06-06 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Reiterato | RBC Capital Mkts | Sector Perform |
Mostra tutto
Puma Biotechnology Inc Borsa (PBYI) Ultime notizie
Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT - MSN
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock Catapults 43% Though Its Price And Business Still Lag The Market - simplywall.st
Puma Biotechnology shares get favourable price bump on strong Q2 results - Mugglehead Magazine
Puma Biotechnology Grants Inducement Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4) - AInvest
Puma Biotechnology Surges 35%: What's Fueling This Biotech Breakout? - AInvest
10 Most Undervalued Biotech Stocks to Buy Now - Insider Monkey
Why is Puma Biotechnology Inc. stock going downStock Picks with Accelerated Return - kangso.co.kr
Results: Puma Biotechnology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - Yahoo Finance
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2025 Earnings Call Transcript - Insider Monkey
Puma Biotechnology 2025 Q2 Earnings Profitability Returns with 229.3% Net Income Surge - AInvest
Puma Biotechnology's Q2 Earnings Outperformance and Nerlynx Momentum Signal a Strategic Buy Opportunity - AInvest
Puma Biotechnology Awards Nearly 28,000 Shares to Three New Employees Under Nasdaq Rule - Stock Titan
Puma Biotechnology Q2 2025 slides: NERLYNX revenue grows 14% quarter-over-quarter - Investing.com India
Earnings call transcript: Puma Biotechnology beats Q2 2025 earnings forecast - Investing.com
Puma Biotechnology Flips To Profit On Cancer Drug Sales - Finimize
Puma Biotechnology Inc (PBYI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Puma Biotech: Q2 Earnings Snapshot - Connecticut Post
Puma Biotechnology 2025 Q2 Earnings Strong Performance as Net Income Surges 229.3% - AInvest
Puma anticipates $192M–$198M NERLYNX revenue for 2025 as company advances alisertib trials - MSN
Puma Biotechnology Reports Second Quarter 2025 Financial Results - BioSpace
Puma Biotechnology Reports Strong Q2 2025 Results - TipRanks
Puma Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Puma Biotechnology: Hold Rating Amid Stable Q2 Performance and Uncertain Trial Outcomes - TipRanks
Puma Biotechnology Anticipates $192M-$198M NERLYNX Revenue for 2025 Amid Alisertib Trials Advancement - AInvest
Puma Biotechnology's Q2 2025: Key Contradictions in Alisertib Strategy, In-Licensing, and Sales Growth - AInvest
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Puma Biotechnology files Form 8-K regarding Q2 2025 results - Stock Titan
Puma Biotechnology Q2 Earnings: From $4.5M Loss to $5.9M Profit as Drug Sales Surge - Stock Titan
Screener Results Flag Puma Biotechnology Inc. as OversoldGrowth Based Investment Plan Guidance Highlighted - metal.it
What are the latest earnings results for Puma Biotechnology Inc.Get professional advice for portfolio optimization - Jammu Links News
How volatile is Puma Biotechnology Inc. stock compared to the marketInvest in high-yield stocks with confidence - Jammu Links News
What drives Puma Biotechnology Inc. stock priceDiscover high-impact stocks for growth - Jammu Links News
How strong is Puma Biotechnology Inc. company’s balance sheetAchieve consistent profits with proven methods - Jammu Links News
What are analysts’ price targets for Puma Biotechnology Inc. in the next 12 monthsFree Market Volatility Navigation Tips - Jammu Links News
What makes Puma Biotechnology Inc. stock price move sharplyOutstanding capital growth - Jammu Links News
What catalysts could drive Puma Biotechnology Inc. stock higher in 2025Tremendous wealth creation - Jammu Links News
Is Puma Biotechnology Inc. a good long term investmentStay ahead with daily market updates - Jammu Links News
What analysts say about Puma Biotechnology Inc. stockInvest confidently with professional market insights - Jammu Links News
What are Puma Biotechnology Inc. company’s key revenue driversUnlock powerful portfolio optimization tools - Jammu Links News
What is the dividend policy of Puma Biotechnology Inc. stockRobust financial gains - Jammu Links News
Is Puma Biotechnology Inc. stock overvalued or undervaluedDiscover market opportunities with expert help - Jammu Links News
Puma Biotechnology (NASDAQ:PBYI) shareholders have endured a 70% loss from investing in the stock five years ago - Yahoo Finance
Puma Biotechnology's Share Price Tanks 70% Over Five Years Despite Becoming Profitable. - AInvest
Volatility clustering patterns for Puma Biotechnology Inc.Daily Breakout List with Smart Filters - Newser
How sentiment analysis helps forecast Puma Biotechnology Inc.Free Fast Entry High Potential Stock Alerts - Newser
How to monitor Puma Biotechnology Inc. with trend dashboardsShort-Term Stock Trend Forecast Guide - Newser
How to use a screener to detect Puma Biotechnology Inc. breakoutsAI Stock Movement Forecast with Accuracy - Newser
Does Puma Biotechnology Inc. stock pay reliable dividendsBeginner Friendly Stock Selection Guide Updated - metal.it
Puma Biotechnology Inc Azioni (PBYI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):